

Andrew M Brunner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3434138/publications.pdf>

Version: 2024-02-01

144
papers

3,280
citations

147801

31
h-index

182427

51
g-index

144
all docs

144
docs citations

144
times ranked

4370
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. <i>Haematologica</i> , 2022, 107, 836-843.	3.5	14
2	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	5.2	5
3	Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. <i>Blood Advances</i> , 2022, 6, 72-81.	5.2	7
4	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	1.6	75
5	Coping strategies in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 2435-2442.	5.2	7
6	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. <i>Leukemia</i> , 2022, 36, 1189-1192.	7.2	5
7	Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. <i>Leukemia and Lymphoma</i> , 2022, 63, 1428-1435.	1.3	3
8	Chemotherapy Resistance in B-ALL with Cryptic <i>NUP214-ABL1</i> Is Amenable to Kinase Inhibition and Immunotherapy. <i>Oncologist</i> , 2022, 27, 82-86.	3.7	5
9	Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. <i>Haematologica</i> , 2022, 107, 2064-2071.	3.5	7
10	Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"? <i>Blood Advances</i> , 2022, 6, 2854-2866.	5.2	3
11	NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 106-117.	4.9	54
12	Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS). <i>Current Problems in Cancer</i> , 2022, 46, 100824.	2.0	3
13	Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia. <i>Journal of Palliative Medicine</i> , 2022, 25, 749-756.	1.1	3
14	TIM-3 pathway dysregulation and targeting in cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 523-534.	2.4	54
15	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. <i>British Journal of Haematology</i> , 2021, 192, 832-842.	2.5	15
16	Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 238.	7.1	90
17	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2500-2506.	4.1	14
18	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	1.4	26

#	ARTICLE	IF	CITATIONS
19	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	7.2	97
20	Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. <i>JAMA Network Open</i> , 2021, 4, e2119812.	5.9	9
21	Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial. <i>Cancer</i> , 2021, 127, 4702-4710.	4.1	12
22	Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. <i>Cancer</i> , 2021, 127, 4339-4347.	4.1	4
23	Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2021, 385, 834-843.	27.0	0
24	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106625.	0.8	0
25	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5502.	3.7	2
26	Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 537-537.	1.4	13
27	Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease. <i>Blood</i> , 2021, 138, 3404-3404.	1.4	1
28	Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 1534-1534.	1.4	2
29	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. <i>Blood</i> , 2021, 138, 244-244.	1.4	60
30	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. <i>Blood</i> , 2021, 138, 3677-3677.	1.4	5
31	Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 2606-2606.	1.4	3
32	Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis. <i>Blood</i> , 2021, 138, 4975-4975.	1.4	0
33	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. <i>Blood</i> , 2021, 138, 1521-1521.	1.4	4
34	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. <i>Blood</i> , 2021, 138, 2158-2158.	1.4	5
35	The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4131-4131.	1.4	0
36	Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2021, 138, 1522-1522.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Evaluating Venetoclax Treatment Duration When Combined with Hypomethylating Agents in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 4412-4412.	1.4	1
38	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020, 105, 161-169.	3.5	15
39	Acute Myeloid Leukemia: A New Era of Therapies, a New Wave of Toxicities?. <i>Acta Haematologica</i> , 2020, 143, 5-6.	1.4	3
40	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	4.1	15
41	Targeting Aberrant Splicing in Myelodysplastic Syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 379-391.	2.2	10
42	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	4.6	19
43	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to induction chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, 245-250.	4.1	13
44	Long-term molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. <i>Leukemia</i> , 2020, 34, 3050-3054.	7.2	3
45	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 3136-3140.	5.2	28
46	Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. <i>Cancer</i> , 2020, 126, 4735-4743.	4.1	11
47	AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S188-S189.	0.4	13
48	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
49	Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e883-e889.	0.4	4
50	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
51	The highs and lows of venetoclax with hypomethylating agents for refractory AML. <i>Leukemia Research</i> , 2020, 91, 106320.	0.8	0
52	Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. <i>Blood Advances</i> , 2020, 4, 106-111.	5.2	23
53	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 294-304.	2.3	17
54	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. <i>Blood</i> , 2020, 136, 15-17.	1.4	9

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	54
56	Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials. <i>Blood</i> , 2020, 136, 31-32.	1.4	3
57	A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for <i>IDH2</i>-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 4-5.	1.4	6
58	Economic Burden of Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Study Using the SEER-Medicare Database. <i>Blood</i> , 2020, 136, 45-45.	1.4	1
59	Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 24-25.	1.4	0
60	Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
61	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
62	A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
63	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 44-45.	1.4	1
64	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. <i>Blood</i> , 2020, 136, 40-42.	1.4	7
65	Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , 2020, 136, 41-42.	1.4	1
66	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 247-254.	3.7	55
67	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. <i>Cancer</i> , 2019, 125, 3845-3852.	4.1	10
68	Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. <i>Blood</i> , 2019, 134, 678-687.	1.4	65
69	Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 3058-3062.	1.3	4
70	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. <i>Leukemia</i> , 2019, 33, 2393-2402.	7.2	44
71	Isocitrate dehydrogenase 1 and 2 mutations, 2-oxoglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	4.1	23
72	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 673-673.	1.4	66

#	ARTICLE	IF	CITATIONS
73	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 565-565.	1.4	46
74	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. <i>Blood</i> , 2019, 134, 2693-2693.	1.4	2
75	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	1.4	64
76	A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2656-2656.	1.4	19
77	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	1.4	3
78	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
79	Genomics in childhood acute myeloid leukemia comes of age. <i>Nature Medicine</i> , 2018, 24, 7-9.	30.7	14
80	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.	1.4	64
81	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018, 124, 306-314.	4.1	23
82	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 254-261.	4.1	12
83	Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 988-991.	1.3	3
84	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	5.2	100
85	NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0007045.	3.0	21
86	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. <i>Cancer</i> , 2018, 124, 4601-4609.	4.1	8
87	Clustered incidence of adult acute promyelocytic leukemia. <i>Leukemia Research</i> , 2018, 74, 47-50.	0.8	2
88	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	5.2	114
89	Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018, 70, 49-55.	0.8	24
90	Incident adverse events following therapy for acute promyelocytic leukemia. <i>Leukemia Research Reports</i> , 2018, 9, 79-83.	0.4	4

#	ARTICLE	IF	CITATIONS
91	Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3425-3434.	2.0	40
92	Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, 1119-1126.	4.1	8
93	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 766-766.	1.4	9
94	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 4059-4059.	1.4	0
95	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	1.4	1
96	Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations. <i>Blood</i> , 2018, 132, 4364-4364.	1.4	0
97	Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2291-2291.	1.4	0
98	Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 4374-4374.	1.4	0
99	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	1.4	4
100	Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria. <i>Blood</i> , 2018, 132, 4378-4378.	1.4	0
101	Outcomes for Older Patients with Acute Myeloid Leukemia after Admission to the Intensive Care Unit (ICU). <i>Blood</i> , 2018, 132, 4750-4750.	1.4	0
102	Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4587-4587.	1.4	0
103	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1431-1431.	1.4	0
104	Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 56-66.	0.3	10
105	Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. <i>American Journal of Clinical Pathology</i> , 2017, 147, aqw203.	0.7	2
106	Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. <i>Lancet Haematology</i> , 2017, 4, e157-e164.	4.6	338
107	Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. <i>Cancer</i> , 2017, 123, 2561-2569.	4.1	33
108	Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. , 2017, 177, 123-128.		23

#	ARTICLE	IF	CITATIONS
109	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 719-727.	3.5	33
110	Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 1111-1118.	2.8	27
111	Development and Validation of a Novel Acute Myeloid Leukemiaâ€œComposite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	7.1	125
112	High-dose Thiotepe, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 884-888.	0.4	14
113	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2017, 1, 2032-2040.	5.2	53
114	H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7075-TPS7075.	1.6	15
115	A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. <i>Leukemia and Lymphoma</i> , 2016, 57, 1-4.	1.3	18
116	Pure White Cell Aplasia and Necrotizing Myositis. <i>Case Reports in Hematology</i> , 2016, 2016, 1-5.	0.4	4
117	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i><scp>FLT</scp>3</i>â€œ<scp>ITD</scp> acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2016, 175, 496-504.	2.5	162
118	Myelodysplastic syndrome associated with acquired beta thalassemia: â€œBTMDSâ€œ. <i>American Journal of Hematology</i> , 2016, 91, E325-7.	4.1	9
119	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	1.4	5
120	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	1.4	18
121	A Retrospective Analysis of Incident Cardiac and Neurological Co-Morbidity Following Treatment of Acute Promyelocytic Leukemia. <i>Blood</i> , 2016, 128, 3994-3994.	1.4	0
122	The Impact of Regional Cardiovascular Care Outcomes on Survival and Cardiovascular-Specific Mortality in Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5984-5984.	1.4	0
123	Health care utilization and endâ€œofâ€œlife care for older patients with acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2840-2848.	4.1	113
124	Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. <i>Leukemia and Lymphoma</i> , 2015, 56, 1698-1703.	1.3	69
125	Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. <i>Leukemia Research Reports</i> , 2015, 4, 28-30.	0.4	0
126	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668.	2.8	31

#	ARTICLE	IF	CITATIONS
127	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1034-1040.	0.8	8
128	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	1.4	6
129	Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015, 126, 532-532.	1.4	6
130	Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1. <i>Blood</i> , 2015, 126, 864-864.	1.4	7
131	The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis. <i>Blood</i> , 2015, 126, 631-631.	1.4	0
132	Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States. <i>Blood</i> , 2015, 126, 3753-3753.	1.4	0
133	New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e334-e340.	3.8	10
134	Presentation to Either the Pediatric Emergency Department or Primary Care Clinic for Acute Illness. <i>Pediatric Emergency Care</i> , 2014, 30, 146-150.	0.9	12
135	Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. <i>Leukemia Research</i> , 2014, 38, 773-780.	0.8	23
136	Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 730-734.	2.0	16
137	A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in Combination with 7+3 Induction Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 119-119.	1.4	2
138	Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations. <i>Blood</i> , 2014, 124, 1045-1045.	1.4	1
139	Trends in all-cause mortality among patients with chronic myeloid leukemia. <i>Cancer</i> , 2013, 119, 2620-2629.	4.1	67
140	Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1374-1380.	2.0	77
141	Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 642-646.	4.1	64
142	Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1434-1437.	1.1	51
143	Splenosis and sepsis: The born-again spleen provides poor protection. <i>Virulence</i> , 2011, 2, 4-11.	4.4	34
144	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. <i>EJHaem</i> , 0, , .	1.0	0